Home > Insider Trading > Filing (0001368148-20-000030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368148	Athersys Inc / New	ATHX	Pharmaceutical Preparations (2834)	204864095

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1402605	K Laura Campbell	3201 Carnegie Avenue Cleveland OH 44115-2634	Senior Vice Pres Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-03-30	44,929	$2.40	561,005	No	4	S	Direct
Common Stock	Disposition	2020-03-31	51,483	$2.90	509,522	No	4	S	Direct
Common Stock	Disposition	2020-04-01	47,339	$3.40	462,183	No	4	S	Direct
Common Stock	Disposition	2020-04-01	47,474	$3.81	414,709	No	4	S	Direct
Common Stock	Disposition	2020-04-01	43,081	$4.26	371,628	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Shares sold pursuant to a predefined Rule 10b5-1 trading plan that commenced in July 2018. A predefined number of shares may be sold from time-to-time based on predefined price increases over a two-year period.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.405, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $2.909, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.44, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.84, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 to $4.285, inclusive.
Securities beneficially owned are comprised of (1) 250,072 shares of common stock owned and (2) unvested restricted stock units aggregating 121,556 related to annual awards, which vest quarterly over a three or four-year period from date of grant.